Type 2 diabetes: the end of clinical inertia.
Mirza
Shirwan A
SA
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008687:Metformin / Q000627:therapeutic use; D009330:Nebulizers and Vaporizers; D010455:Peptides / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000627:therapeutic use; D014230:Triazoles / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010455:Peptides; D011719:Pyrazines; D045162:Thiazolidinediones; D014230:Triazoles; D014688:Venoms; D000069036:Insulin Glargine; D008687:Metformin; D000077270:Exenatide; D000068900:Sitagliptin Phosphate